News Conference News ESC 2025 Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF Michael O'Riordan August 29, 2025
News Conference News European Congress on Obesity 2025 Obesity-Related Cancer Rates No Different With GLP-1s vs Bariatric Surgery Michael O'Riordan May 14, 2025
News Conference News SCAI 2025 When Early Cardiogenic Shock Isn’t Dealt With, Outcomes Can Suffer L.A. McKeown May 09, 2025
News Conference News ACC 2025 Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP Michael O'Riordan April 01, 2025
News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025
News Conference News AHA 2024 REALIZE-K: Potassium Binder Boosts MRA Use in Hyperkalemic HFrEF Patients L.A. McKeown November 22, 2024
News Conference News AHA 2024 Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD Yael L. Maxwell November 16, 2024
News Conference News AHA 2024 US Obesity Epidemic Continues to Skyrocket, With No End in Sight Michael O'Riordan November 15, 2024
News Conference News VIVA 2024 Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II L.A. McKeown November 06, 2024
News Conference News ESC 2024 FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients Michael O'Riordan September 01, 2024
News Conference News ESC 2024 Stop-or-Not: It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery Todd Neale August 30, 2024
News Conference News SCCT 2024 Coronary Calcium Scoring May Help Get Semaglutide to Highest-Risk Patients Todd Neale July 22, 2024
News Conference News SCCT 2024 Incidental CAC Tied to Worse Outcomes in Systemic Inflammatory Diseases Todd Neale July 21, 2024
News Conference News ESC Heart Failure 2024 Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients Michael O'Riordan May 13, 2024
News Conference News SCAI 2024 CALORI: More Support for Eschewing Fasting Protocols Preprocedure L.A. McKeown May 02, 2024
News Conference News ACC 2024 KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives Shelley Wood April 11, 2024
News Conference News AHA 2023 New CVD Risk Tool Can Spur Even Earlier Talk About Prevention Yael L. Maxwell November 14, 2023
News Conference News AHA 2023 Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics Todd Neale November 11, 2023
News Conference News ESC 2023 ESC Focused Update on HF Synthesizes New Trial Data for Practical Use L.A. McKeown September 01, 2023
News Conference News ESC 2023 New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground Caitlin E. Cox August 30, 2023